◀ Back to CD79B

CD79B — SRC

Text-mined interactions from Literome

Gazumyan et al., J Exp Med 2006 : BCR cross linking resulted in decreased Src and Syk activation but paradoxically enhanced and prolonged BCR signaling, as measured by cellular tyrosine phosphorylation, Ca ( ++ ) flux, AKT, and ERK activation
Konig et al., Blood 2008 (Leukemia, Myelogenous, Chronic, BCR-ABL Positive) : SKI-606 effectively inhibited Bcr-Abl kinase activity in CML CD34 ( + ) cells and inhibited Src phosphorylation more potently than imatinib
Konig et al., Cancer Res 2008 (Leukemia, Myelogenous, Chronic, BCR-ABL Positive) : In contrast, Imatinib inhibited only Bcr-Abl dependent Src activity
Mahon et al., Cancer Res 2008 (Leukemia, Myelogenous, Chronic, BCR-ABL Positive) : Two Src kinase inhibitors ( PP1 and PP2 ) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity ... In contrast, dasatinib, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn
Takata et al., FEBS Lett 1995 : These results demonstrate that the BCR induced phosphorylation of Src-PTK is independent of Syk and that the kinase activity of Src-PTK is critical for BCR signaling